Lampalizumab

From WikiMD's Wellnesspedia

Lampalizumab is an experimental drug that was developed by Genentech, a biotechnology company based in the United States. The drug was designed to treat geographic atrophy, a form of age-related macular degeneration (AMD) that can lead to severe vision loss and blindness.

History[edit | edit source]

Lampalizumab was first developed by Genentech, a member of the Roche Group. The drug was designed to target and inhibit the activity of complement factor D, a protein that plays a key role in the development of geographic atrophy.

In 2013, Genentech announced the results of a Phase II clinical trial, which suggested that lampalizumab could slow the progression of geographic atrophy. However, two Phase III clinical trials (known as the Spectri and Chroma trials) failed to confirm these results.

Mechanism of Action[edit | edit source]

Lampalizumab is a monoclonal antibody that targets complement factor D. By inhibiting this protein, the drug is thought to reduce the inflammatory response that contributes to the development of geographic atrophy.

Clinical Trials[edit | edit source]

The Phase II clinical trial of lampalizumab, known as the Mahalo trial, suggested that the drug could slow the progression of geographic atrophy. However, the Phase III Spectri and Chroma trials failed to confirm these results.

In the Spectri trial, patients treated with lampalizumab did not experience a significant reduction in the progression of geographic atrophy compared to those treated with a placebo. Similarly, in the Chroma trial, there was no significant difference in the progression of geographic atrophy between patients treated with lampalizumab and those treated with a placebo.

Future Development[edit | edit source]

Following the results of the Spectri and Chroma trials, Genentech announced that it would not seek regulatory approval for lampalizumab as a treatment for geographic atrophy. However, the company stated that it would continue to investigate other potential treatments for this condition.

See Also[edit | edit source]


Lampalizumab Resources

Find a healthcare provider anywhere in the world quickly and easily!

Wiki.png

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD


Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.


Contributors: Prab R. Tumpati, MD